Literature DB >> 9561491

Sample size determination for repeated measurements in bioequivalence test.

K J Lui1.   

Abstract

When the measurement of outcome is unreliable or the cost of obtaining an additional subject is relatively high compared to the cost of obtaining an additional measurement from the same subject, it may be desirable to consider taking more than one measurement per subject to increase power or to minimize the cost in a clinical trial. When each subject in two comparison groups has a fixed number of repeated measurements, this paper develops an asymptotic procedure to calculate the number of subjects per group required to achieve a given power for an a-level bioequivalence test. Furthermore, Monte Carlo simulation is used to evaluate the accuracy of the approximate sample size calculation procedure and a brief discussion on how to determine the optimal number of repeated measurements is included.

Mesh:

Year:  1997        PMID: 9561491     DOI: 10.1023/a:1025749210833

Source DB:  PubMed          Journal:  J Pharmacokinet Biopharm        ISSN: 0090-466X


  9 in total

1.  Sample size determination for the two one-sided tests procedure in bioequivalence.

Authors:  J P Liu; S C Chow
Journal:  J Pharmacokinet Biopharm       Date:  1992-02

2.  Sample size requirement for repeated measurements in continuous data.

Authors:  K J Lui; W G Cumberland
Journal:  Stat Med       Date:  1992-03       Impact factor: 2.373

3.  A comparison of the two one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability.

Authors:  D J Schuirmann
Journal:  J Pharmacokinet Biopharm       Date:  1987-12

4.  Significance testing to establish equivalence between treatments, with special reference to data in the form of 2X2 tables.

Authors:  C W Dunnett; M Gent
Journal:  Biometrics       Date:  1977-12       Impact factor: 2.571

5.  Statistical aspects of comparative bioavailability trials.

Authors:  W J Westlake
Journal:  Biometrics       Date:  1979-03       Impact factor: 2.571

6.  A proposal for interpreting and reporting negative studies.

Authors:  W W Hauck; S Anderson
Journal:  Stat Med       Date:  1986 May-Jun       Impact factor: 2.373

7.  Sample size requirements and the cost of a randomized clinical trial with repeated measurements.

Authors:  D A Bloch
Journal:  Stat Med       Date:  1986 Nov-Dec       Impact factor: 2.373

8.  An exact confidence interval from untransformed data for the ratio of two formulation means.

Authors:  C S Locke
Journal:  J Pharmacokinet Biopharm       Date:  1984-12

9.  A new statistical procedure for testing equivalence in two-group comparative bioavailability trials.

Authors:  W W Hauck; S Anderson
Journal:  J Pharmacokinet Biopharm       Date:  1984-02
  9 in total
  2 in total

1.  Sample size computations for PK/PD population models.

Authors:  Dongwoo Kang; Janice B Schwartz; Davide Verotta
Journal:  J Pharmacokinet Pharmacodyn       Date:  2005-12       Impact factor: 2.745

2.  LDL-cholesterol lowering effect of a generic product of simvastatin compared to simvastatin (Zocor) in Thai hypercholesterolemic subjects -- a randomized crossover study, the first report from Thailand.

Authors:  Viroj Wiwanitkit; Danai Wangsaturaka; Oranee Tangphao
Journal:  BMC Clin Pharmacol       Date:  2002-01-30
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.